Check out the top 5 nutrition articles of 2025. A case of painful plantar nodules in a 10-year-old boy following hot tub exposure was consistent with Pseudomonas hot-foot syndrome, a self-limited form ...

In this recap article, take a look back at some of our top stories in the infectious diseases space in 2025. Welcome to another edition of our Countdown to 2026! In this article, we take you through ...

Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

Clinicians now have the first oral alternative to injectable therapy for gonorrhea, a shift Angela Hasler, APRN, CPNP-PC says could ease treatment barriers and improve public health outcomes.

The FDA approved Daybue Stix, a powder formulation of trofinetide, for Rett syndrome in patients 2 years or older. New formulation, same clinical expectations: The FDA approval of DAYBUE STIX provides ...

The FDA approved omidubicel on December 8, 2025, the same day parent company Ayrmid announced positive results at the 2025 American Society of Hematology Annual Meeting and Exposition. FDA approved ...

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades. Phase 3 data demonstrated noninferiority to ceftriaxone plus ...

“Having a drug that [patients] can be confident in that will be highly effective as well as well tolerated is a great advantage," said Edward Hook, MD. The FDA recently approved Nuzolvence ...

“We took a different approach by looking at colonizing bacteria, and we found vaccination reduced antimicrobial resistance through a completely different mechanism," said Brooke Ramay, lead author of ...

Following an updated policy from the American Academy of Child and Adolescent Psychiatry, Joshua Feder, MD, explains why providers should present DRBIs and NDBIs as options for autism care.

According to multiple reports, the FDA is investigating the safety of a pair of already-approved protective treatments for respiratory syncytial virus. The FDA is launching a new safety review of the ...